155 related articles for article (PubMed ID: 27067842)
1. [Molecular Subtypes of Gastric Cancer].
Hatogai K; Doi T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):281-5. PubMed ID: 27067842
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
[TBL] [Abstract][Full Text] [Related]
3. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
4. Emerging molecular classifications and therapeutic implications for gastric cancer.
Chen T; Xu XY; Zhou PH
Chin J Cancer; 2016 May; 35():49. PubMed ID: 27233623
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular characterization of gastric adenocarcinoma.
Cancer Genome Atlas Research Network
Nature; 2014 Sep; 513(7517):202-9. PubMed ID: 25079317
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
7. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
Koltz BR; Hicks DG; Whitney-Miller CL
Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
[TBL] [Abstract][Full Text] [Related]
9. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
10. [Relation of HER2 status and prognosis in gastric cancer patients].
Fuse N
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1073-8. PubMed ID: 21772089
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
Lordick F
Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
[TBL] [Abstract][Full Text] [Related]
13. Molecular classification of gastric cancer.
Röcken C
Expert Rev Mol Diagn; 2017 Mar; 17(3):293-301. PubMed ID: 28118758
[TBL] [Abstract][Full Text] [Related]
14. Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer.
Lim B; Kim JH; Kim M; Kim SY
World J Gastroenterol; 2016 Jan; 22(3):1190-201. PubMed ID: 26811657
[TBL] [Abstract][Full Text] [Related]
15. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network.
Sunakawa Y; Lenz HJ
Curr Treat Options Oncol; 2015 Apr; 16(4):17. PubMed ID: 25813036
[TBL] [Abstract][Full Text] [Related]
17. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
18. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
Daum O; Skálová A; Rozkos T; Laco J
Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
[TBL] [Abstract][Full Text] [Related]
19. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
20. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
